The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Mult Scler Relat Disord
; 8: 131-5, 2016 Jul.
Article
em En
| MEDLINE
| ID: mdl-27456888
ABSTRACT
BACKGROUND:
Various molecules of the coagulation cascade are thought to have varying roles in the pathophysiology of multiple sclerosis (MS). We aimed to find new information about the effects of the coagulation cascade molecules to develop new therapeutic strategies for MS. MATERIALS ANDMETHODS:
Patients with MS were chosen from among patients who were followed up at our hospital. We examined the thrombomodulin (TM) and activated protein C (APC) serum levels in patients with MS and the healthy controls. The patient groups were determined as relapsing-remitting MS (RRMS) or secondary progressive MS (SPMS) according to the McDonald criteria and between ages of 18 and 70.RESULTS:
A total of 244 participants, 122 patients with multiple sclerosis and 122 healthy volunteers were included in the study. There was no statistically significant difference in the APC and TM levels between the patients and the healthy controls (p>0.05), between the patients with RRMS and SPMS (p>0.05), and between the first day of acute relapse and 10th day of methylprednisolone therapy in the patients with RRMS (p=0.334; p=0.363). We detected a statistically positive correlation only between the expanded disability status scale (EDSS) scores and TM levels in the patient group (p=0.009).CONCLUSION:
Treatment with methylprednisolone decreases EDSS score in RRMS relapse. The increase in EDSS is related to level of TM. The changes in level of TM and APC may be indicator for prognosis of MS or treatment modalities to MS.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteína C
/
Trombomodulina
/
Esclerose Múltipla Crônica Progressiva
/
Esclerose Múltipla Recidivante-Remitente
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article